190 related articles for article (PubMed ID: 35501730)
21. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Reiter A; Lengfelder E; Grimwade D
Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
[TBL] [Abstract][Full Text] [Related]
22. Application of bone marrow samples for discrimination of acute promyelocytic leukemia from other types of acute leukemia using the routine automated hematology analyzer.
Jang MJ; Choi HW; Lee SY; Lee OJ; Kim HR; Shin JH; Suh SP; Ryang DW; Shin MG
Int J Lab Hematol; 2014 Oct; 36(5):531-40. PubMed ID: 24410923
[TBL] [Abstract][Full Text] [Related]
23. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
[TBL] [Abstract][Full Text] [Related]
24. PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
Yang X; Tan Y; Wang P; Zhang H; Zhao M; Zhao X; Wang K
J Cell Mol Med; 2018 Dec; 22(12):6275-6284. PubMed ID: 30320491
[TBL] [Abstract][Full Text] [Related]
25. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
26. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a droplet digital PCR assay for the evaluation of PML-RARα fusion transcripts in acute promyelocytic leukemia.
Jiang XW; Chen SZ; Zhu XY; Xu XX; Liu Y
Mol Cell Probes; 2020 Oct; 53():101617. PubMed ID: 32585184
[TBL] [Abstract][Full Text] [Related]
28. [Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].
Wang YZ; Chang Y; Zhu HH; Qin YZ; Li JL; Fu JY; Li LD; Chen SS; Huang XJ; Lu DP; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):427-32. PubMed ID: 16800913
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
Gau JP; Young JH; Lin TH; Yang YS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412
[TBL] [Abstract][Full Text] [Related]
30. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of minimal residual disease in children with acute promyelocytic leukemia by RT-PCR detecting PML/RARalpha chimeric gene: a retrospective study of clinical feasibility.
Suzuki H; Imaizumi M; Sato A; Yoshinari M; Rikiishi T; Endo M; Takano T; Shimizu T; Hatae Y; Fujimoto T; Hayashi Y; Iinuma K
Tohoku J Exp Med; 2001 Feb; 193(2):127-39. PubMed ID: 11318028
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
Inokuchi K; Iwakiri R; Futaki M; Hanawa H; Tanosaki S; Nomura T; Dan K
Leuk Lymphoma; 1998 May; 29(5-6):553-61. PubMed ID: 9643569
[TBL] [Abstract][Full Text] [Related]
33. Expression of human Krüppel-like factor 3 in peripheral blood as a promising biomarker for acute leukemia.
Yan M; Liu H; Xu J; Cen X; Wang Q; Xu W; Wang W; Qiu Z; Ou J; Dong Y; Zhu P; Ren H; He F; Wang M
Cancer Med; 2020 Apr; 9(8):2803-2811. PubMed ID: 32101374
[TBL] [Abstract][Full Text] [Related]
34. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
35. LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.
Wang X; Lin Q; Lv F; Liu N; Xu Y; Liu M; Chen Y; Yi Z
Leukemia; 2016 Jul; 30(7):1465-74. PubMed ID: 27012866
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of a patient with
Jiang YZ; Wei ZL; Wang NN; Huang C; Huang J; Yan JW; Wang R; Yu ZZ; Huang DP
Hematology; 2022 Dec; 27(1):1290-1293. PubMed ID: 36476114
[TBL] [Abstract][Full Text] [Related]
37. Treatment concepts of acute promyelocytic leukemia.
Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
39. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia.
Grimwade D; Lo Coco F
Leukemia; 2002 Oct; 16(10):1959-73. PubMed ID: 12357347
[TBL] [Abstract][Full Text] [Related]
40. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Ramos Perez JM; Patel KP; Loghavi S; Garcia-Manero G; Borthakur G; Jabbour E; Wierda W; Pierce S; Brandt M; Kornblau S; Kadia T; Daver N; DiNardo CD; Jain N; Yilmaz M; Short N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Rivera D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2022 Mar; 63(3):672-675. PubMed ID: 34668451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
